Annual balance sheet for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | 2026 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 14.1 | 5.14 | 0.376 | 3.95 | 0.711 |
| Net Total Receivables | 0 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 14.4 | 5.84 | 0.455 | 4.18 | 1.76 |
| Net Property, Plant And Equipment | 0.103 | 0.08 | 0.176 | 0.426 | 0.315 |
| Total Assets | 14.5 | 5.92 | 0.632 | 4.6 | 2.08 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.16 | 2.87 | 3.23 | 0.635 | 1.35 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.16 | 2.87 | 3.23 | 0.635 | 1.35 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 13.4 | 3.05 | -2.59 | 3.97 | 0.733 |
| Total Liabilities & Shareholders' Equity | 14.5 | 5.92 | 0.632 | 4.6 | 2.08 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |